{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:05:03Z","timestamp":1792710303358,"version":"4.5.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The objective of this initiative was to develop a treat-to-target (T2T) approach for the management of patients with Familial Mediterranean Fever (FMF), including the definition of a complex treatment target, and establish strategies that improve patient care and long-term outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An initial set of statements as well as a flow chart visualising the proposed concept was developed. To adapt the preliminary statements to the current state of knowledge, a systematic literature search was performed and the modified statements were subject to a Delphi approach. To ensure the applicability of the statements in daily practice, an online survey was conducted among paediatric rheumatologists in Germany. In addition, data from the national AID-NET registry were analysed with respect to therapeutic response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>This T2T initiative yielded a total of 26 statements guiding FMF management with respect to diagnosis, treatment targets, treatment strategies and monitoring. The online survey identified cut-off values for inflammatory markers indicating treatment intensification and appropriate measures in case of colchicine intolerance or non-adherence. The analysis of data derived from the national AID-NET showed that colchicine therapy was successfully terminated in 61% of patients (27 out of 44) with heterozygous <jats:italic>MEFV<\/jats:italic> mutations. Multidimensional treatment targets incorporating objective and subjective reported outcome measures were developed. These provide the basis for stratifying patients into the following treatment paths: continue colchicine, persisting attacks \/ inflammation, colchicine intolerance, persisting arthritis, colchicine reduction and adjustment\/reduction of biologics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The proposed consensus treatment plan for the management of FMF incorporates multidimensional targets allowing transparent treatment decisions, which will promote personalised disease management and increase adherence to therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-023-00875-y","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T09:02:28Z","timestamp":1695718948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Treat-to-target strategies for the management of familial Mediterranean Fever in children"],"prefix":"10.1186","volume":"21","author":[{"given":"Lisa","family":"Ehlers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Rolfes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Lieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Lainka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faekah","family":"Gohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Klaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Girschick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"H\u00f6rstermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"K\u00fcmmerle-Deschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Palm-Beden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Tenbrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lusine","family":"von Wrangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fa\u00dfhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Trauzeddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sae Lim","family":"von Stuckrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Welzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Hentgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Foell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Wittkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2404-9397","authenticated-orcid":false,"given":"Tilmann","family":"Kallinich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"875_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219137","author":"DM Schwartz","year":"2021","unstructured":"Schwartz DM, Kitakule MM, Dizon BL, et al. Systematic evaluation of nine monogenic autoinflammatory diseases reveals common and disease-specific correlations with allergy-associated features. Ann Rheum Dis Published Online First: 22 February. 2021. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219137.","journal-title":"Ann Rheum Dis Published Online First: 22 February"},{"key":"875_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0002-9343(67)90167-2","volume":"43","author":"E Sohar","year":"1967","unstructured":"Sohar E, Gafni J, Pras M, et al. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43:227\u201353. https:\/\/doi.org\/10.1016\/0002-9343(67)90167-2.","journal-title":"Am J Med"},{"key":"875_CR3","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/art.22507","volume":"56","author":"I Touitou","year":"2007","unstructured":"Touitou I, Sarkisian T, Medlej-Hashim M, et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum. 2007;56:1706\u201312. https:\/\/doi.org\/10.1002\/art.22507.","journal-title":"Arthritis Rheum"},{"key":"875_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s0092-8674(00)80539-5","volume":"90","author":"Ancient missense mutations","year":"1997","unstructured":"Ancient missense mutations. In a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Int FMF Consortium Cell. 1997;90:797\u2013807. https:\/\/doi.org\/10.1016\/s0092-8674(00)80539-5.","journal-title":"Int FMF Consortium Cell"},{"key":"875_CR5","doi-asserted-by":"publisher","first-page":"9982","DOI":"10.1073\/pnas.0602081103","volume":"103","author":"JJ Chae","year":"2006","unstructured":"Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A. 2006;103:9982\u20137. https:\/\/doi.org\/10.1073\/pnas.0602081103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"875_CR6","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41590-020-0705-6","volume":"21","author":"YH Park","year":"2020","unstructured":"Park YH, Remmers EF, Lee W, et al. Ancient familial Mediterranean fever mutations in human pyrin and resistance to Yersinia pestis. Nat Immunol. 2020;21:857\u201367. https:\/\/doi.org\/10.1038\/s41590-020-0705-6.","journal-title":"Nat Immunol"},{"key":"875_CR7","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s00431-012-1803-8","volume":"171","author":"E Lainka","year":"2012","unstructured":"Lainka E, Bielak M, Lohse P, et al. Familial Mediterranean fever in Germany: epidemiological, clinical, and genetic characteristics of a pediatric population. Eur J Pediatr. 2012;171:1775\u201385. https:\/\/doi.org\/10.1007\/s00431-012-1803-8.","journal-title":"Eur J Pediatr"},{"key":"875_CR8","first-page":"2445","volume":"25","author":"S Ozen","year":"1998","unstructured":"Ozen S, Karaaslan Y, Ozdemir O, et al. Prevalence of juvenile chronic arthritis and familial Mediterranean fever in Turkey: a field study. J Rheumatol. 1998;25:2445\u20139.","journal-title":"J Rheumatol"},{"key":"875_CR9","unstructured":"Sarkisian T, Ajrapetian H, Beglarian A et al. Familial Mediterranean Fever in armenian population. Georgian Med News 2008;:105\u201311."},{"key":"875_CR10","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/1756-185X.13259","volume":"21","author":"NS Yasar Bilge","year":"2018","unstructured":"Yasar Bilge NS, Sari I, Solmaz D, et al. Comparison of early versus late onset familial Mediterranean fever. Int J Rheum Dis. 2018;21:880\u20134. https:\/\/doi.org\/10.1111\/1756-185X.13259.","journal-title":"Int J Rheum Dis"},{"key":"875_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/14397595.2020.1719594","volume":"31","author":"A Tanatar","year":"2021","unstructured":"Tanatar A, Karada\u011f \u015eG, \u00c7akan M, et al. Age of onset as an influencing factor for disease severity in children with familial Mediterranean fever. Mod Rheumatol. 2021;31:219\u201322. https:\/\/doi.org\/10.1080\/14397595.2020.1719594.","journal-title":"Mod Rheumatol"},{"key":"875_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/rhu.0000000000001637","author":"D Gezgin Yildirim","year":"2020","unstructured":"Gezgin Yildirim D, G\u00f6nen S, Fidan K, et al. Does Age at Onset affect the clinical presentation of familial Mediterranean Fever in Children? J Clin Rheumatol Published Online First: 24 November. 2020. https:\/\/doi.org\/10.1097\/rhu.0000000000001637.","journal-title":"J Clin Rheumatol Published Online First: 24 November"},{"key":"875_CR13","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s10067-016-3196-y","volume":"35","author":"S \u00d6zdel","year":"2016","unstructured":"\u00d6zdel S, \u00d6z\u00e7akar ZB, Kunt S, et al. Late-onset disease is associated with a mild phenotype in children with familial Mediterranean fever. Clin Rheumatol. 2016;35:1837\u201340. https:\/\/doi.org\/10.1007\/s10067-016-3196-y.","journal-title":"Clin Rheumatol"},{"key":"875_CR14","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2015-208690","volume":"75","author":"S Ozen","year":"2016","unstructured":"Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75:644\u201351. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208690.","journal-title":"Ann Rheum Dis"},{"key":"875_CR15","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/art.1780340806","volume":"34","author":"D Zemer","year":"1991","unstructured":"Zemer D, Livneh A, Danon YL, et al. Long-term colchicine treatment in children with familial mediterranean fever. Arthr Rhuem. 1991;34:973\u20137. https:\/\/doi.org\/10.1002\/art.1780340806.","journal-title":"Arthr Rhuem"},{"key":"875_CR16","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/BF00441519","volume":"148","author":"HA Majeed","year":"1989","unstructured":"Majeed HA, Barakat M. Familial mediterranean fever (recurrent hereditary polyserositis) in children: analysis of 88 cases. Eur J Pediatr. 1989;148:636\u201341. https:\/\/doi.org\/10.1007\/BF00441519.","journal-title":"Eur J Pediatr"},{"key":"875_CR17","doi-asserted-by":"publisher","unstructured":"Lachmann HJ. Long-Term Complications of Familial Mediterranean Fever. In: Gattorno M, ed. Familial Mediterranean Fever. Cham:: Springer International Publishing 2015. 91\u2013105. doi:https:\/\/doi.org\/10.1007\/978-3-319-14615-7_6.","DOI":"10.1007\/978-3-319-14615-7_6"},{"key":"875_CR18","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","volume":"378","author":"F De Benedetti","year":"2018","unstructured":"De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the treatment of Autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378:1908\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1706314.","journal-title":"N Engl J Med"},{"key":"875_CR19","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/annrheumdis-2020-217419","volume":"79","author":"S Ozen","year":"2020","unstructured":"Ozen S, Ben-Cherit E, Foeldvari I, et al. Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial. Ann Rheum Dis. 2020;79:1362\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217419.","journal-title":"Ann Rheum Dis"},{"key":"875_CR20","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/art.39995","volume":"69","author":"I Ben-Zvi","year":"2017","unstructured":"Ben-Zvi I, Kukuy O, Giat E, et al. Anakinra for Colchicine-Resistant Familial Mediterranean Fever: a Randomized, Double-Blind, placebo-controlled trial. Arthritis Rheumatol. 2017;69:854\u201362. https:\/\/doi.org\/10.1002\/art.39995.","journal-title":"Arthritis Rheumatol"},{"key":"875_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/14397595.2019.1709258","volume":"31","author":"S Colak","year":"2021","unstructured":"Colak S, Tekgoz E, Cinar M, et al. The assessment of tocilizumab therapy on recurrent attacks of patients with familial Mediterranean fever: a retrospective study of 15 patients. Mod Rheumatol. 2021;31:223\u20135. https:\/\/doi.org\/10.1080\/14397595.2019.1709258.","journal-title":"Mod Rheumatol"},{"key":"875_CR22","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s10067-012-2009-1","volume":"31","author":"ZB \u00d6z\u00e7akar","year":"2012","unstructured":"\u00d6z\u00e7akar ZB, Y\u00fcksel S, Ekim M, et al. Infliximab therapy for familial Mediterranean fever-related amyloidosis: case series with long term follow-up. Clin Rheumatol. 2012;31:1267\u201371. https:\/\/doi.org\/10.1007\/s10067-012-2009-1.","journal-title":"Clin Rheumatol"},{"key":"875_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12969-018-0257-6","volume":"16","author":"CH Hinze","year":"2018","unstructured":"Hinze CH, Oommen PT, Dressler F, et al. Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria. Pediatr Rheumatol Online J. 2018;16:40. https:\/\/doi.org\/10.1186\/s12969-018-0257-6.","journal-title":"Pediatr Rheumatol Online J"},{"key":"875_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77:819\u201328. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213030.","journal-title":"Ann Rheum Dis"},{"key":"875_CR25","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1136\/annrheumdis-2019-216843","volume":"79","author":"A Klein","year":"2020","unstructured":"Klein A, Minden K, Hospach A, et al. Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis. Ann Rheum Dis. 2020;79:969\u201374. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216843.","journal-title":"Ann Rheum Dis"},{"key":"875_CR26","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1093\/rheumatology\/kex222","volume":"56","author":"AM Knieper","year":"2017","unstructured":"Knieper AM, Klotsche J, Lainka E, et al. Familial Mediterranean fever in children and adolescents: factors for colchicine dosage and predicting parameters for dose increase. Rheumatology (Oxford). 2017;56:1597\u2013606. https:\/\/doi.org\/10.1093\/rheumatology\/kex222.","journal-title":"Rheumatology (Oxford)"},{"key":"875_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00393-018-0588-1","volume":"78","author":"T Kallinich","year":"2019","unstructured":"Kallinich T, Blank N, Braun T, et al. [Evidence-based treatment recommendations for familial Mediterranean fever: a joint statement by the Society for Pediatric and adolescent rheumatology and the german society for Rheumatology]. Z Rheumatol. 2019;78:91\u2013101. https:\/\/doi.org\/10.1007\/s00393-018-0588-1.","journal-title":"Z Rheumatol"},{"key":"875_CR28","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1136\/annrheumdis-2013-203666","volume":"73","author":"M Piram","year":"2014","unstructured":"Piram M, Kon\u00e9-Paut I, Lachmann HJ, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis. 2014;73:2168\u201373. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203666.","journal-title":"Ann Rheum Dis"},{"key":"875_CR29","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/annrheumdis-2013-204719","volume":"73","author":"S Ozen","year":"2014","unstructured":"Ozen S, Demirkaya E, Duzova A, et al. FMF50: a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis. 2014;73:897\u2013901. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204719.","journal-title":"Ann Rheum Dis"},{"key":"875_CR30","first-page":"129","volume":"34","author":"D Konukbay","year":"2016","unstructured":"Konukbay D, Gattorno M, Yildiz D, et al. A novel assessment tool for clinical care of patients with autoinflammatory disease: juvenile autoinflammatory disease multidimensional assessment report. Clin Exp Rheumatol. 2016;34:129\u201335.","journal-title":"Clin Exp Rheumatol"},{"key":"875_CR31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1136\/annrheumdis-2015-208671","volume":"75","author":"E Demirkaya","year":"2016","unstructured":"Demirkaya E, Acikel C, Hashkes P, et al. Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF). Ann Rheum Dis. 2016;75:1051\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208671.","journal-title":"Ann Rheum Dis"},{"key":"875_CR32","unstructured":"Oxford Centre for Evidence-Based Medicine. : Levels of Evidence (March 2009). https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009."},{"key":"875_CR33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.semarthrit.2013.04.011","volume":"43","author":"V Hentgen","year":"2013","unstructured":"Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of familial Mediterranean Fever. Semin Arthritis Rheum. 2013;43:387\u201391. https:\/\/doi.org\/10.1016\/j.semarthrit.2013.04.011.","journal-title":"Semin Arthritis Rheum"},{"key":"875_CR34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4103\/ajm.AJM_78_17","volume":"7","author":"A Alsarah","year":"2017","unstructured":"Alsarah A, Alsara O, Laird-Fick HS. Cardiac manifestations of familial Mediterranean fever. Avicenna J Med. 2017;7:158\u201363. https:\/\/doi.org\/10.4103\/ajm.AJM_78_17.","journal-title":"Avicenna J Med"},{"key":"875_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00296-017-3853-8","volume":"38","author":"E Erken","year":"2018","unstructured":"Erken E. Cardiac disease in familial Mediterranean fever. Rheumatol Int. 2018;38:51\u20138. https:\/\/doi.org\/10.1007\/s00296-017-3853-8.","journal-title":"Rheumatol Int"},{"key":"875_CR36","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/rheumatology\/kei279","volume":"45","author":"HJ Lachmann","year":"2006","unstructured":"Lachmann HJ, Seng\u00fcl B, Yavuz\u015fen TU, et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford). 2006;45:746\u201350. https:\/\/doi.org\/10.1093\/rheumatology\/kei279.","journal-title":"Rheumatology (Oxford)"},{"key":"875_CR37","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1136\/ard.2009.114363","volume":"69","author":"T Kallinich","year":"2010","unstructured":"Kallinich T, Wittkowski H, Keitzer R, et al. Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever. Ann Rheum Dis. 2010;69:677\u201382. https:\/\/doi.org\/10.1136\/ard.2009.114363.","journal-title":"Ann Rheum Dis"},{"key":"875_CR38","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1136\/annrheumdis-2011-201271","volume":"71","author":"Y Shinar","year":"2012","unstructured":"Shinar Y, Obici L, Aksentijevich I, et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis. 2012;71:1599\u2013605. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201271.","journal-title":"Ann Rheum Dis"},{"key":"875_CR39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrrheum.2013.174","volume":"10","author":"S Ozen","year":"2014","unstructured":"Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol. 2014;10:135\u201347. https:\/\/doi.org\/10.1038\/nrrheum.2013.174.","journal-title":"Nat Rev Rheumatol"},{"key":"875_CR40","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/jmedgenet-2017-105216","volume":"55","author":"ME Van Gijn","year":"2018","unstructured":"Van Gijn ME, Ceccherini I, Shinar Y, et al. New workflow for classification of genetic variants\u2019 pathogenicity applied to hereditary recurrent fevers by the International Study Group for systemic Autoinflammatory Diseases (INSAID). J Med Genet. 2018;55:530\u20137. https:\/\/doi.org\/10.1136\/jmedgenet-2017-105216.","journal-title":"J Med Genet"},{"key":"875_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/cge.13223","volume":"94","author":"S Gangemi","year":"2018","unstructured":"Gangemi S, Manti S, Procopio V, et al. Lack of clear and univocal genotype-phenotype correlation in familial Mediterranean fever patients: a systematic review. Clin Genet. 2018;94:81\u201394. https:\/\/doi.org\/10.1111\/cge.13223.","journal-title":"Clin Genet"},{"key":"875_CR42","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3899\/jrheum.141249","volume":"43","author":"E Demirkaya","year":"2016","unstructured":"Demirkaya E, Saglam C, Turker T, et al. Performance of different diagnostic criteria for familial Mediterranean Fever in children with periodic fevers: results from a Multicenter International Registry. J Rheumatol. 2016;43:154\u201360. https:\/\/doi.org\/10.3899\/jrheum.141249.","journal-title":"J Rheumatol"},{"key":"875_CR43","first-page":"41","volume":"31","author":"M La Regina","year":"2013","unstructured":"La Regina M, Ben-Chetrit E, Gasparyan AY, et al. Current trends in colchicine treatment in familial Mediterranean fever. Clin Exp Rheumatol. 2013;31:41\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"875_CR44","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s10067-014-2598-y","volume":"33","author":"F Ozaltin","year":"2014","unstructured":"Ozaltin F, Bilginer Y, G\u00fclhan B, et al. Diagnostic validity of colchicine in patients with familial Mediterranean fever. Clin Rheumatol. 2014;33:969\u201374. https:\/\/doi.org\/10.1007\/s10067-014-2598-y.","journal-title":"Clin Rheumatol"},{"key":"875_CR45","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1001\/archinte.1961.03620040065007","volume":"107","author":"H Heller","year":"1961","unstructured":"Heller H, Sohar E, Gafni J, et al. Amyloidosis in familial Mediterranean fever. An independent genetically determined character. Arch Intern Med. 1961;107:539\u201350. https:\/\/doi.org\/10.1001\/archinte.1961.03620040065007.","journal-title":"Arch Intern Med"},{"key":"875_CR46","first-page":"818","volume":"12","author":"AM Al-Wahadneh","year":"2006","unstructured":"Al-Wahadneh AM, Dahabreh MM. Familial Mediterranean fever in children: a single centre experience in Jordan. East Mediterr Health J. 2006;12:818\u201323.","journal-title":"East Mediterr Health J"},{"key":"875_CR47","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/s1590-8658(00)80008-0","volume":"32","author":"AM Ozel","year":"2000","unstructured":"Ozel AM, Demirt\u00fcrk L, Yazgan Y, et al. Familial Mediterranean fever. A review of the disease and clinical and laboratory findings in 105 patients. Dig Liver Dis. 2000;32:504\u20139. https:\/\/doi.org\/10.1016\/s1590-8658(00)80008-0.","journal-title":"Dig Liver Dis"},{"key":"875_CR48","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/art.37935","volume":"65","author":"V Hentgen","year":"2013","unstructured":"Hentgen V, Grateau G, Stankovic-Stojanovic K, et al. Familial Mediterranean fever in heterozygotes: are we able to accurately diagnose the disease in very young children? Arthritis Rheum. 2013;65:1654\u201362. https:\/\/doi.org\/10.1002\/art.37935.","journal-title":"Arthritis Rheum"},{"key":"875_CR49","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3389\/fimmu.2020.00865","volume":"11","author":"A Soriano","year":"2020","unstructured":"Soriano A, Soriano M, Espinosa G, et al. Current therapeutic options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: evidence-based Approach and proposal of a practical guide. Front Immunol. 2020;11:865. https:\/\/doi.org\/10.3389\/fimmu.2020.00865.","journal-title":"Front Immunol"},{"key":"875_CR50","doi-asserted-by":"publisher","first-page":"e2019027","DOI":"10.4084\/mjhid.2019.027","volume":"11","author":"R Manna","year":"2019","unstructured":"Manna R, Rigante D. Familial Mediterranean Fever: assessing the overall clinical impact and formulating treatment plans. Mediterr J Hematol Infect Dis. 2019;11:e2019027. https:\/\/doi.org\/10.4084\/mjhid.2019.027.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"875_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00296-019-04412-7","volume":"40","author":"N Atas","year":"2020","unstructured":"Atas N, Armagan B, Bodakci E, et al. Familial Mediterranean fever is associated with a wide spectrum of inflammatory disorders: results from a large cohort study. Rheumatol Int. 2020;40:41\u20138. https:\/\/doi.org\/10.1007\/s00296-019-04412-7.","journal-title":"Rheumatol Int"},{"key":"875_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/rhu.0000000000001134","volume":"27","author":"M \u00c7akan","year":"2021","unstructured":"\u00c7akan M, Karada\u011f \u015eG, Tanatar A, et al. The value of serum amyloid A levels in familial Mediterranean Fever to identify occult inflammation during asymptomatic periods. J Clin Rheumatol. 2021;27:1\u20134. https:\/\/doi.org\/10.1097\/rhu.0000000000001134.","journal-title":"J Clin Rheumatol"},{"key":"875_CR53","first-page":"113","volume":"33","author":"M Lieber","year":"2015","unstructured":"Lieber M, Kallinich T, Lohse P, et al. Increased serum concentrations of neutrophil-derived protein S100A12 in heterozygous carriers of MEFV mutations. Clin Exp Rheumatol. 2015;33:113\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"875_CR54","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1002\/art.39784","volume":"68","author":"F Gohar","year":"2016","unstructured":"Gohar F, Orak B, Kallinich T, et al. Correlation of secretory activity of neutrophils with genotype in patients with familial Mediterranean Fever. Arthritis Rheumatol. 2016;68:3010\u201322. https:\/\/doi.org\/10.1002\/art.39784.","journal-title":"Arthritis Rheumatol"},{"key":"875_CR55","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00296-015-3413-z","volume":"36","author":"B Erer","year":"2016","unstructured":"Erer B, Demirkaya E, Ozen S, et al. What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review. Rheumatol Int. 2016;36:483\u20137. https:\/\/doi.org\/10.1007\/s00296-015-3413-z.","journal-title":"Rheumatol Int"},{"key":"875_CR56","doi-asserted-by":"publisher","unstructured":"Piram M, Frenkel J, Gattorno M et al. A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. Ann Rheum Dis 2011;70:309\u201314. doi:https:\/\/doi.org\/10.1136\/ard.2010.132613.","DOI":"10.1136\/ard.2010.132613"},{"key":"875_CR57","doi-asserted-by":"publisher","unstructured":"Pras E, Livneh A, Balow JE Jr, et al. Clinical differences between north african and iraqi Jews with familial Mediterranean fever. Am J Med Genet. 1998;75:216\u20139. https:\/\/doi.org\/10.1002\/(sici)1096-8628(19980113)75:2<216::aid-ajmg20>3.0.co;2-r.","DOI":"10.1002\/(sici)1096-8628(19980113)75:2<216::aid-ajmg20>3.0.co;2-r"},{"key":"875_CR58","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.semarthrit.2005.02.002","volume":"35","author":"A Mor","year":"2005","unstructured":"Mor A, Shinar Y, Zaks N, et al. Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum. 2005;35:57\u201364. https:\/\/doi.org\/10.1016\/j.semarthrit.2005.02.002.","journal-title":"Semin Arthritis Rheum"},{"key":"875_CR59","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00393-020-00886-0","volume":"79","author":"T Sahr","year":"2020","unstructured":"Sahr T, Kiltz U, Weseloh C, et al. [Results of the systematic literature search as basis for the \u2018Evidence-based treatment recommendations for familial Mediterranean fever patients with insufficient response or intolerability to colchicine\u2019 of the Society for Pediatric and adolescent rheumatology and the german society for Rheumatology]. Z Rheumatol. 2020;79:943\u201351. https:\/\/doi.org\/10.1007\/s00393-020-00886-0.","journal-title":"Z Rheumatol"},{"key":"875_CR60","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1542\/peds.2006-1434","volume":"119","author":"T Kallinich","year":"2007","unstructured":"Kallinich T, Haffner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007;119:e474\u201383. https:\/\/doi.org\/10.1542\/peds.2006-1434.","journal-title":"Pediatrics"},{"key":"875_CR61","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.semarthrit.2019.05.011","volume":"49","author":"O Goldberg","year":"2019","unstructured":"Goldberg O, Levinsky Y, Peled O, et al. Age dependent safety and efficacy of colchicine treatment for familial mediterranean fever in children. Semin Arthritis Rheum. 2019;49:459\u201363. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.05.011.","journal-title":"Semin Arthritis Rheum"},{"key":"875_CR62","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13075-016-0980-7","volume":"18","author":"A Polat","year":"2016","unstructured":"Polat A, Acikel C, Sozeri B, et al. Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever\u2013a randomized controlled noninferiority trial. Arthritis Res Ther. 2016;18:85. https:\/\/doi.org\/10.1186\/s13075-016-0980-7.","journal-title":"Arthritis Res Ther"},{"key":"875_CR63","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/14397595.2020.1790139","volume":"31","author":"E Baglan","year":"2021","unstructured":"Baglan E, Ozdel S, Bulbul M. Do all colchicine preparations have the same effectiveness in patients with familial Mediterranean fever? Mod Rheumatol. 2021;31:481\u20134. https:\/\/doi.org\/10.1080\/14397595.2020.1790139.","journal-title":"Mod Rheumatol"},{"key":"875_CR64","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1002\/art.24570","volume":"60","author":"D Marek-Yagel","year":"2009","unstructured":"Marek-Yagel D, Berkun Y, Padeh S, et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum. 2009;60:1862\u20136. https:\/\/doi.org\/10.1002\/art.24570.","journal-title":"Arthritis Rheum"},{"key":"875_CR65","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.3906\/sag-2001-261","volume":"50","author":"H Sati\u015f","year":"2020","unstructured":"Sati\u015f H, Arma\u011fan B, Bodak\u00e7i E, et al. Colchicine intolerance in FMF patients and primary obstacles for optimal dosing. Turk J Med Sci. 2020;50:1337\u201343. https:\/\/doi.org\/10.3906\/sag-2001-261.","journal-title":"Turk J Med Sci"},{"key":"875_CR66","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13023-017-0609-1","volume":"12","author":"A Corsia","year":"2017","unstructured":"Corsia A, Georgin-Lavialle S, Hentgen V, et al. A survey of resistance to colchicine treatment for french patients with familial Mediterranean fever. Orphanet J Rare Dis. 2017;12:54. https:\/\/doi.org\/10.1186\/s13023-017-0609-1.","journal-title":"Orphanet J Rare Dis"},{"key":"875_CR67","doi-asserted-by":"publisher","unstructured":"Tekg\u00f6z E, \u00c7olak S, \u00c7inar FI, et al. Non-adherence to colchicine treatment is a common misevaluation in familial Mediterranean fever. Turk J Med Sci Published Online First: 7. May 2021. https:\/\/doi.org\/10.3906\/sag-2102-328.","DOI":"10.3906\/sag-2102-328"},{"key":"875_CR68","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jpeds.2020.03.065","volume":"224","author":"E Sag","year":"2020","unstructured":"Sag E, Bayindir Y, Adiguzel A, et al. Colchicine and Leukopenia: clinical implications. J Pediatr. 2020;224:166\u2013170e1. https:\/\/doi.org\/10.1016\/j.jpeds.2020.03.065.","journal-title":"J Pediatr"},{"key":"875_CR69","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.3906\/sag-2009-187","volume":"51","author":"Y T\u00fcrkmeno\u011flu","year":"2021","unstructured":"T\u00fcrkmeno\u011flu Y, G\u00fcney E, Bezen D, et al. Evaluation of S100A12 protein levels in children with familial Mediterranean fever. Turk J Med Sci. 2021;51:1396\u2013405. https:\/\/doi.org\/10.3906\/sag-2009-187.","journal-title":"Turk J Med Sci"},{"key":"875_CR70","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00296-017-3796-0","volume":"38","author":"K Barut","year":"2018","unstructured":"Barut K, Sahin S, Adrovic A, et al. Familial Mediterranean fever in childhood: a single-center experience. Rheumatol Int. 2018;38:67\u201374. https:\/\/doi.org\/10.1007\/s00296-017-3796-0.","journal-title":"Rheumatol Int"},{"key":"875_CR71","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00296-015-3227-z","volume":"35","author":"MT Bayram","year":"2015","unstructured":"Bayram MT, \u00c7ankaya T, Bora E, et al. Risk factors for subclinical inflammation in children with familial Mediterranean fever. Rheumatol Int. 2015;35:1393\u20138. https:\/\/doi.org\/10.1007\/s00296-015-3227-z.","journal-title":"Rheumatol Int"},{"key":"875_CR72","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s10067-018-4359-9","volume":"38","author":"Y Yamasaki","year":"2019","unstructured":"Yamasaki Y, Takei S, Imanaka H, et al. S100A12 and vascular endothelial growth factor can differentiate Blau syndrome and familial Mediterranean fever from systemic juvenile idiopathic arthritis. Clin Rheumatol. 2019;38:835\u201340. https:\/\/doi.org\/10.1007\/s10067-018-4359-9.","journal-title":"Clin Rheumatol"},{"key":"875_CR73","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/03009742.2018.1558282","volume":"48","author":"O Varan","year":"2019","unstructured":"Varan O, Kucuk H, Babaoglu H, et al. Chronic inflammation in adult familial Mediterranean fever patients: underlying causes and association with amyloidosis. Scand J Rheumatol. 2019;48:315\u20139. https:\/\/doi.org\/10.1080\/03009742.2018.1558282.","journal-title":"Scand J Rheumatol"},{"key":"875_CR74","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361\u201371. https:\/\/doi.org\/10.1056\/NEJMoa070265.","journal-title":"N Engl J Med"},{"key":"875_CR75","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.rdc.2018.06.004","volume":"44","author":"R Papa","year":"2018","unstructured":"Papa R, Lachmann HJ, Secondary AA, Amyloidosis. Rheumatic Disease Clinics of North America. 2018;44:585\u2013603. https:\/\/doi.org\/10.1016\/j.rdc.2018.06.004.","journal-title":"Rheumatic Disease Clinics of North America"},{"key":"875_CR76","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/CLEP.S39981","volume":"6","author":"DR de As\u00faa","year":"2014","unstructured":"de As\u00faa DR, Costa R, Galv\u00e1n JM, et al. Systemic AA amyloidosis: epidemiology, diagnosis, and management. CLEP. 2014;6:369\u201377. https:\/\/doi.org\/10.2147\/CLEP.S39981.","journal-title":"CLEP"},{"key":"875_CR77","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3390\/medicina57101049","volume":"57","author":"R Siligato","year":"2021","unstructured":"Siligato R, Gembillo G, Calabrese V, et al. Amyloidosis and glomerular Diseases in Familial Mediterranean Fever. Med (Kaunas). 2021;57:1049. https:\/\/doi.org\/10.3390\/medicina57101049.","journal-title":"Med (Kaunas)"},{"key":"875_CR78","unstructured":"Yesilkaya S, Acikel C, Fidanci BE et al. Development of a medication adherence scale for familial Mediterranean fever (MASIF) in a cohort of turkish children.;:7."},{"key":"875_CR79","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1093\/rheumatology\/keaa121","volume":"59","author":"E Sag","year":"2020","unstructured":"Sag E, Akal F, Atalay E, et al. Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry. Rheumatology (Oxford). 2020;59:3324\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keaa121.","journal-title":"Rheumatology (Oxford)"},{"key":"875_CR80","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40272-019-00354-6","volume":"21","author":"RM Kisla Ekinci","year":"2019","unstructured":"Kisla Ekinci RM, Balci S, Dogruel D, et al. Canakinumab in Children with Familial Mediterranean Fever: a Single-Center, retrospective analysis. Paediatr Drugs. 2019;21:389\u201395. https:\/\/doi.org\/10.1007\/s40272-019-00354-6.","journal-title":"Paediatr Drugs"},{"key":"875_CR81","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semarthrit.2017.03.006","volume":"47","author":"S Ozen","year":"2017","unstructured":"Ozen S, Kone-Paut I, G\u00fcl A. Colchicine resistance and intolerance in familial mediterranean fever: definition, causes, and alternative treatments. Semin Arthritis Rheum. 2017;47:115\u201320. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.006.","journal-title":"Semin Arthritis Rheum"},{"key":"875_CR82","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s42358-020-0117-1","volume":"60","author":"A \u015eahin","year":"2020","unstructured":"\u015eahin A, Derin ME, Albayrak F, et al. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant\/unresponsive familial Mediterranean fever. Adv Rheumatol. 2020;60:12. https:\/\/doi.org\/10.1186\/s42358-020-0117-1.","journal-title":"Adv Rheumatol"},{"key":"875_CR83","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejim.2020.11.001","volume":"84","author":"A Fayand","year":"2021","unstructured":"Fayand A, Savey L, Ducharme-B\u00e9nard S, et al. Prescription of interleukin-1 inhibitors in a french adult cohort of familial Mediterranean fever. Eur J Intern Med. 2021;84:109\u201311. https:\/\/doi.org\/10.1016\/j.ejim.2020.11.001.","journal-title":"Eur J Intern Med"},{"key":"875_CR84","doi-asserted-by":"publisher","first-page":"230","DOI":"10.5152\/eurjrheum.2018.18036","volume":"5","author":"BM K\u00f6hler","year":"2018","unstructured":"K\u00f6hler BM, Lorenz H-M, Blank N. IL1-blocking therapy in colchicine-resistant familial Mediterranean fever. Eur J Rheumatol. 2018;5:230\u20134. https:\/\/doi.org\/10.5152\/eurjrheum.2018.18036.","journal-title":"Eur J Rheumatol"},{"key":"875_CR85","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1093\/rheumatology\/keaa211","volume":"59","author":"S Ugurlu","year":"2020","unstructured":"Ugurlu S, Ergezen B, Egeli BH, et al. Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford). 2020;59:3892\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keaa211.","journal-title":"Rheumatology (Oxford)"},{"key":"875_CR86","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00296-019-04366-w","volume":"40","author":"S Eren Akarcan","year":"2020","unstructured":"Eren Akarcan S, Dogantan S, Edeer Karaca N, et al. Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review. Rheumatol Int. 2020;40:161\u20138. https:\/\/doi.org\/10.1007\/s00296-019-04366-w.","journal-title":"Rheumatol Int"},{"key":"875_CR87","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/RHU.0000000000000873","volume":"26","author":"H Babaoglu","year":"2020","unstructured":"Babaoglu H, Varan O, Kucuk H, et al. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -intolerant adult familial Mediterranean Fever Patients: a Single-Center Real-Life Study. J Clin Rheumatol. 2020;26:7\u201313. https:\/\/doi.org\/10.1097\/RHU.0000000000000873.","journal-title":"J Clin Rheumatol"},{"key":"875_CR88","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10067-018-4230-z","volume":"38","author":"H Babaoglu","year":"2019","unstructured":"Babaoglu H, Varan O, Kucuk H, et al. On demand use of anakinra for attacks of familial Mediterranean fever (FMF). Clin Rheumatol. 2019;38:577\u201381. https:\/\/doi.org\/10.1007\/s10067-018-4230-z.","journal-title":"Clin Rheumatol"},{"key":"875_CR89","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0049-0172(97)80007-8","volume":"27","author":"P Langevitz","year":"1997","unstructured":"Langevitz P, Livneh A, Zemer D, et al. Seronegative spondyloarthropathy in familial Mediterranean fever. Semin Arthritis Rheum. 1997;27:67\u201372. https:\/\/doi.org\/10.1016\/s0049-0172(97)80007-8.","journal-title":"Semin Arthritis Rheum"},{"key":"875_CR90","first-page":"435","volume":"24","author":"O Sakallioglu","year":"2006","unstructured":"Sakallioglu O, Duzova A, Ozen S. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clin Exp Rheumatol. 2006;24:435\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"875_CR91","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1750-1172-9-3","volume":"9","author":"I Ben-Zvi","year":"2014","unstructured":"Ben-Zvi I, Krichely-Vachdi T, Feld O, et al. Colchicine-free remission in familial Mediterranean fever: featuring a unique subset of the disease-a case control study. Orphanet J Rare Dis. 2014;9:3. https:\/\/doi.org\/10.1186\/1750-1172-9-3.","journal-title":"Orphanet J Rare Dis"},{"key":"875_CR92","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10067-016-3421-8","volume":"36","author":"HE S\u00f6nmez","year":"2017","unstructured":"S\u00f6nmez HE, Batu ED, Bilginer Y, et al. Discontinuing colchicine in symptomatic carriers for MEFV (Mediterranean FeVer) variants. Clin Rheumatol. 2017;36:421\u20135. https:\/\/doi.org\/10.1007\/s10067-016-3421-8.","journal-title":"Clin Rheumatol"},{"key":"875_CR93","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201158","author":"Y Butbul Aviel","year":"2021","unstructured":"Butbul Aviel Y, Rawan S, Fahoum S, et al. Discontinuation of Colchicine Therapy in Children with Familial Mediterranean Fever. J Rheumatol Published Online First: 15 May. 2021. https:\/\/doi.org\/10.3899\/jrheum.201158.","journal-title":"J Rheumatol Published Online First: 15 May"},{"key":"875_CR94","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/s0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755\u201362. https:\/\/doi.org\/10.1016\/s0140-6736(98)04311-6.","journal-title":"Lancet"},{"key":"875_CR95","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"DM Nathan","year":"1993","unstructured":"Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977\u201386. https:\/\/doi.org\/10.1056\/NEJM199309303291401.","journal-title":"N Engl J Med"},{"key":"875_CR96","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/rheumatology\/keaa659","volume":"60","author":"K Mankia","year":"2021","unstructured":"Mankia K, Gul H, Emery P. Treating rheumatoid arthritis to an imaging target produces better outcomes, or does it? Rheumatology. 2021;60:3\u20134. https:\/\/doi.org\/10.1093\/rheumatology\/keaa659.","journal-title":"Rheumatology"},{"key":"875_CR97","doi-asserted-by":"publisher","unstructured":"\u00d6zen S, Sag E, Ben-Chetrit E et al. Defining colchicine resistance\/intolerance in patients with familial Mediterranean fever: a modified-Delphi consensus approach. Rheumatology (Oxford) Published Online First: 17 December 2020. doi:https:\/\/doi.org\/10.1093\/rheumatology\/keaa863.","DOI":"10.1093\/rheumatology\/keaa863"},{"key":"875_CR98","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/1756-185X.13514","volume":"22","author":"H Benham","year":"2019","unstructured":"Benham H, Rutherford M, Kirby S, et al. Treat-to-target in rheumatoid arthritis: evaluating the patient perspective using the patient Opinion Real-Time Anonymous Liaison system: the RA T2T PORTAL study. Int J Rheum Dis. 2019;22:874\u20139. https:\/\/doi.org\/10.1111\/1756-185X.13514.","journal-title":"Int J Rheum Dis"},{"key":"875_CR99","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/rheumatology\/ker421","volume":"51","author":"G Kalkan","year":"2012","unstructured":"Kalkan G, Demirkaya E, Acikel CH, et al. Evaluation of the current disease severity scores in paediatric FMF: is it necessary to develop a new one? Rheumatology (Oxford). 2012;51:743\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/ker421.","journal-title":"Rheumatology (Oxford)"},{"key":"875_CR100","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1136\/ard.2008.092031","volume":"68","author":"S Ozen","year":"2009","unstructured":"Ozen S, Aktay N, Lainka E, et al. Disease severity in children and adolescents with familial Mediterranean fever: a comparative study to explore environmental effects on a monogenic disease. Ann Rheum Dis. 2009;68:246\u20138. https:\/\/doi.org\/10.1136\/ard.2008.092031.","journal-title":"Ann Rheum Dis"},{"key":"875_CR101","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1136\/annrheumdis-2018-213725","volume":"77","author":"NM Ter Haar","year":"2018","unstructured":"Ter Haar NM, van Delft ALJ, Annink KV, et al. In silico validation of the autoinflammatory disease damage index. Ann Rheum Dis. 2018;77:1599\u2013605. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213725.","journal-title":"Ann Rheum Dis"},{"key":"875_CR102","first-page":"97","volume":"36","author":"A Erden","year":"2018","unstructured":"Erden A, Batu ED, Sar\u0131 A, et al. Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever? Clin Exp Rheumatol. 2018;36:97\u2013102.","journal-title":"Clin Exp Rheumatol"},{"key":"875_CR103","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/dmcn.12932","volume":"58","author":"C Imms","year":"2016","unstructured":"Imms C, Adair B, Keen D, et al. Participation\u2019: a systematic review of language, definitions, and constructs used in intervention research with children with disabilities. Dev Med Child Neurol. 2016;58:29\u201338. https:\/\/doi.org\/10.1111\/dmcn.12932.","journal-title":"Dev Med Child Neurol"},{"key":"875_CR104","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5606\/ArchRheumatol.2019.7198","volume":"34","author":"RM Ki\u015fla Ekinci","year":"2019","unstructured":"Ki\u015fla Ekinci RM, Balci S, Akay E, et al. Disease severity and genotype affect physical growth in Children with Familial Mediterranean Fever. Arch Rheumatol. 2019;34:288\u201393. https:\/\/doi.org\/10.5606\/ArchRheumatol.2019.7198.","journal-title":"Arch Rheumatol"},{"key":"875_CR105","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.clinbiochem.2016.11.008","volume":"50","author":"K Stankovic Stojanovic","year":"2017","unstructured":"Stankovic Stojanovic K, Hentgen V, Fellahi S, et al. Concordance between CRP and SAA in familial Mediterranean fever during attack-free period: a study of 218 patients. Clin Biochem. 2017;50:206\u20139. https:\/\/doi.org\/10.1016\/j.clinbiochem.2016.11.008.","journal-title":"Clin Biochem"},{"key":"875_CR106","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/art.10944","volume":"48","author":"R Gershoni-Baruch","year":"2003","unstructured":"Gershoni-Baruch R, Brik R, Zacks N, et al. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum. 2003;48:1149\u201355. https:\/\/doi.org\/10.1002\/art.10944.","journal-title":"Arthritis Rheum"},{"key":"875_CR107","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/s0002-9297(07)62944-9","volume":"67","author":"C Cazeneuve","year":"2000","unstructured":"Cazeneuve C, Ajrapetyan H, Papin S, et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet. 2000;67:1136\u201343. https:\/\/doi.org\/10.1016\/s0002-9297(07)62944-9.","journal-title":"Am J Hum Genet"},{"key":"875_CR108","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/rheumatology\/kez156","volume":"58","author":"A Tanatar","year":"2019","unstructured":"Tanatar A, Karada\u011f \u015e G, S\u00f6nmez HE, et al. Short-term follow-up results of children with familial Mediterranean fever after cessation of colchicine: is it possible to quit? Rheumatology (Oxford). 2019;58:1818\u201321. https:\/\/doi.org\/10.1093\/rheumatology\/kez156.","journal-title":"Rheumatology (Oxford)"},{"key":"875_CR109","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/acr.23446","volume":"70","author":"S Akar","year":"2018","unstructured":"Akar S, Cetin P, Kalyoncu U, et al. Nationwide experience with off-label use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients. Arthritis Care Res (Hoboken). 2018;70:1090\u20134. https:\/\/doi.org\/10.1002\/acr.23446.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"875_CR110","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1093\/rheumatology\/keaa596","volume":"60","author":"S Ugurlu","year":"2021","unstructured":"Ugurlu S, Ergezen B, Egeli BH, et al. Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience. Rheumatology (Oxford). 2021;60:2327\u201332. https:\/\/doi.org\/10.1093\/rheumatology\/keaa596.","journal-title":"Rheumatology (Oxford)"},{"key":"875_CR111","doi-asserted-by":"publisher","first-page":"175","DOI":"10.24953\/turkjped.2020.02.002","volume":"62","author":"DG Y\u0131ld\u0131r\u0131m","year":"2020","unstructured":"Y\u0131ld\u0131r\u0131m DG, Fidan HK, G\u00f6nen S, et al. Sacroiliitis associated with familial Mediterranean fever in childhood: a case series and review of literature. Turk J Pediatr. 2020;62:175\u201381. https:\/\/doi.org\/10.24953\/turkjped.2020.02.002.","journal-title":"Turk J Pediatr"},{"key":"875_CR112","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5152\/eurjrheum.2020.20126","volume":"8","author":"DY Kehribar","year":"2021","unstructured":"Kehribar DY, \u00d6zgen M. Efficacy of anti-interleukin-1 treatment in colchicine-resistant arthritis in patients with familial Mediterranean fever. Eur J Rheumatol. 2021;8:16\u20139. https:\/\/doi.org\/10.5152\/eurjrheum.2020.20126.","journal-title":"Eur J Rheumatol"},{"key":"875_CR113","doi-asserted-by":"publisher","first-page":"568865","DOI":"10.3389\/fphar.2020.568865","volume":"11","author":"V Hentgen","year":"2020","unstructured":"Hentgen V, Kon\u00e9-Paut I, Belot A, et al. Long-term Follow-Up and optimization of Interleukin-1 inhibitors in the management of Monogenic Autoinflammatory Diseases: Real-Life Data from the JIR Cohort. Front Pharmacol. 2020;11:568865. https:\/\/doi.org\/10.3389\/fphar.2020.568865.","journal-title":"Front Pharmacol"},{"key":"875_CR114","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/1756-185X.13891","volume":"23","author":"T Kurt","year":"2020","unstructured":"Kurt T, Ayd\u0131n F, Nil\u00fcfer Tekg\u00f6z P, et al. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: a single-center experience. Int J Rheum Dis. 2020;23:977\u201381. https:\/\/doi.org\/10.1111\/1756-185X.13891.","journal-title":"Int J Rheum Dis"},{"key":"875_CR115","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13023-017-0642-0","volume":"12","author":"S Ugurlu","year":"2017","unstructured":"Ugurlu S, Hacioglu A, Adibnia Y, et al. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever. Orphanet J Rare Dis. 2017;12:105. https:\/\/doi.org\/10.1186\/s13023-017-0642-0.","journal-title":"Orphanet J Rare Dis"},{"key":"875_CR116","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.3390\/jcm11185360","volume":"11","author":"JC Henes","year":"2022","unstructured":"Henes JC, Saur S, Kofler DM, et al. Tocilizumab for the treatment of familial Mediterranean Fever\u2014A Randomized, Double-Blind, placebo-controlled phase II study. J Clin Med. 2022;11:5360. https:\/\/doi.org\/10.3390\/jcm11185360.","journal-title":"J Clin Med"},{"key":"875_CR117","first-page":"2620","volume":"30","author":"M Lidar","year":"2003","unstructured":"Lidar M, Kedem R, Langevitz P, et al. Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine. J Rheumatol. 2003;30:2620\u20133.","journal-title":"J Rheumatol"},{"key":"875_CR118","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00296-019-04348-y","volume":"40","author":"R Tal","year":"2020","unstructured":"Tal R, Semo Oz R, Amarilyo G, et al. Safety and efficacy of intravenous colchicine in children with familial Mediterranean Fever. Rheumatol Int. 2020;40:121\u20138. https:\/\/doi.org\/10.1007\/s00296-019-04348-y.","journal-title":"Rheumatol Int"},{"key":"875_CR119","unstructured":"Rozenbaum M, Boulman N, Feld J et al. Intravenous colchicine treatment for six months: adjunctive therapy in familial Mediterranean fever (FMF) unresponsive to oral colchicine. In: Clin Exp Rheumatol. Italy: 2009. S105."},{"key":"875_CR120","first-page":"1050","volume":"56","author":"Deaths from","year":"2007","unstructured":"Deaths from. Intravenous colchicine resulting from a compounding pharmacy error\u2013oregon and Washington, 2007. MMWR Morb Mortal Wkly Rep. 2007;56:1050\u20132.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"875_CR121","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00296-019-04490-7","volume":"40","author":"H Karadeniz","year":"2020","unstructured":"Karadeniz H, G\u00fcler AA, Atas N, et al. Tofacitinib for the treatment for colchicine-resistant familial Mediterranean fever: case-based review. Rheumatol Int. 2020;40:169\u201373. https:\/\/doi.org\/10.1007\/s00296-019-04490-7.","journal-title":"Rheumatol Int"},{"key":"875_CR122","first-page":"88","volume":"42","author":"K G\u00f6k","year":"2017","unstructured":"G\u00f6k K, Cengiz G, Erol K, et al. Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever. Acta Reumatol Port. 2017;42:88\u201390.","journal-title":"Acta Reumatol Port"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00875-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00875-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00875-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T14:19:50Z","timestamp":1700230790000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00875-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":122,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["875"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00875-y","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"assertion":[{"value":"10 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Lisa Ehlers has no conflicts of interest to declare. Elisabeth Rolfes has no conflicts of interest to declare. Mareike Lieber is a member of the following medical society: GKJR. Dominik M\u00fcller has no conflicts of interest to declare. Elke Lainka received consulting fees from Mirum and Albireo. Faekah Gohar has no conflicts of interest to declare. G\u00fcnter Klaus has no conflicts of interest to declare. Hermann Girschick was involved in the development of treatment guidelines of the following societies: DGKJ. Jana H\u00f6rstermann has no conflicts of interest to declare. Jasmin K\u00fcmmerle-Deschner received consulting fees, honoraria and research grants from Novartis and SOBI, and is a member of the following medical societies: GKJR, DGRh, PRES, ISSAID. J\u00fcrgen Brunner received honoraria for presenting at industrial symposia and is a member of the following medical societies: DGKJ, \u00d6GKJ, \u00d6GR, GKJR, DGPI. Katharina Palm-Beden has no conflicts of interest to declare. Klaus Tenbrock received consulting fees from Pfizer and Novartis, a research grant from Pfizer, and was involved in the development of treatment guidelines of the following societies: GKJR. Lusine von Wrangel has no conflicts of interest to declare. Maria Fa\u00dfhauer has no conflicts of interest to declare. Norbert Blank received consulting fees, honoraria and research grants from Novartis and SOBI, and is a member of the following medical societies: DGRh, DNSS, ISA. Ralf Trauzeddel received consulting fees from Novartis and was involved in the development of a treatment guideline of the following society: AWMF. Anne Sae Lim von Stuckrad has no conflicts of interest to declare. Sonja Higgins has no conflicts of interest to declare. Tatjana Welzel has no conflicts of interest to declare. Thomas Lutz is a member of the following medical societies: GKJR, DGKJ, DGPI. V\u00e9ronique Hentgen has received consulting fees and honoraria from Novartis and SOBI, is a member of the steering committee of the JIRcohort which received public and private funding for research, and is involved in the development of French guidelines on behalf of the Haute Autorit\u00e9 de Sant\u00e9 (HAS). She is a member of the following medical societies:SOFREMIP, PReS and ISSAID. Dirk Foell received research funding from Novartis and Sobi, honoraria from Novartis and Sobi, and is a member of the following medical societies: GKJR, API, ISSAID, PReS, GPGE, and DGKJ. Helmut Wittkowski received research funding from Takeda, honoraria from Novartis and Takeda, travel grants from Octapharma and CSL-Behring, and is a member of the following medical societies: GKJR, API. Tilmann Kallinich is a member of the following medical societies: GKJR and DGPI.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"108"}}